Author

Naglaa M. Ahmed

Observed name: Ahmed, Naglaa M.

Institutions: Capital University, Helwan University

Observed institutions: Capital University, Helwan University

ORCID: 0000-0001-5864-2370

Observed ORCID: 0000-0001-5864-2370

OpenAlex ID: A5128732878

Pyrazole/pyrimidine derivatives endowed with azobenzenes as dual EGFR T790M and VEGFR-2 inhibitors: anticancer, docking, synthesis, design and ADMET assessments

2026 · Kurls E. Anwer, Mohamed A. Abdelgawad, et al. · RSC Advances · 14

Fourth-generation allosteric EGFR inhibitors: Structure-based scaffold analysis and SAR exploration

2026 · Ibrahim Mohammed Hepishy, Mo'men Salem, et al. · Bioorganic Chemistry · 1

Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors

2026 · Naglaa M. Ahmed, Rizk E. Khidre, et al. · Bioorganic Chemistry

Pyrimidine‐Derived Scaffolds Targeting VEGFR‐2, EGFR, and HER‐2: Synthesis, Anticancer/Immunomodulatory Evaluation, and In Silico Analysis

2026 · Naglaa M. Ahmed, Mohamed S. Gaballah, et al. · Drug Development Research

Evaluation of new 5-benzylidenethiazolidin-2,4-dione derivatives linked to nitric oxide donor oxime moiety as VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative assessment and in silico studies

2026 · El-Hameed, Abeer M. Abd, Ahmed, Naglaa M., et al. · Figshare

Evaluation of new 5-benzylidenethiazolidin-2,4-dione derivatives linked to nitric oxide donor oxime moiety as VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative assessment and in silico studies

2026 · Abeer M. Abd El-Hameed, Naglaa M. Ahmed, et al. · Future Medicinal Chemistry

Author response for "Pyrazole/pyrimidine derivatives endowed with azobenzenes as dual EGFR T790M and VEGFR-2 inhibitors: Anticancer, docking, synthesis, design and ADMET assessments"

2026 · Kurls E. Anwer, Mohamed A. Abdelgawad, et al. · Publons reviews and discussion

Author response for "Pyrazole/pyrimidine derivatives endowed with azobenzenes as dual EGFR T790M and VEGFR-2 inhibitors: Anticancer, docking, synthesis, design and ADMET assessments"

2025 · Kurls E. Anwer, Mohamed A. Abdelgawad, et al. · Publons reviews and discussion

Works count: 9

Citation count: 15

H-index: 1

I10-index: 1